Research Paper Volume 12, Issue 18 pp 18676—18692
Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer
Figure 7. Expression levels of MMP14 and PKM2 in different subtypes of patients with pancreatic cancer. (A) Box plots demonstrated the expression levels of MMP14 and PKM2 in different subtypes of patients with pancreatic cancer in TCGA datasets. P values were determined using Student’s t test. (B) Box plots demonstrated the expression levels of MMP14 and PKM2 in different grades of patients with pancreatic cancer in GSE78829 dataset. (C) Contingency graphs showed the number of patients with KRAS or CDKN2A alterations in different clinical responsiveness. P values were determined by Chi-square test. (D) Box plots demonstrated the expression levels of MMP14 and PKM2 in treatment responsive or un-responsive patients with pancreatic cancer.